Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Speeda Rabies Vaccine Post-Marketing Study for Category III Bites
NCT01827917Phase 4Completed
- Sponsor
- Beijing Center for Disease Control and Prevention
- Start
- Feb 2013
- Primary completion
- Dec 2013
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of SPEEDA + TRCS SPEEDA in rabies, sponsored by Beijing Center for Disease Control and Prevention. Primary endpoint: Observation of the subject after injured by the animals carrying the virus at 2 years. Started Feb 2013; status: completed.
02
Drugs
SPEEDA + TRCS SPEEDA
03
Conditions
rabies
Beyond the preview
Go deeper on NCT01827917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01827917.